H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95 [Yahoo! Finance]
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
Cathie Wood buys $2 million of tumbling AI stock [Yahoo! Finance]
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
Tempus AI (TEM) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.